{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:44:07Z","timestamp":1789530247321,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) has been implicated in cognitive decline through vascular and metabolic pathways, yet evidence linking it to dementia remains inconsistent. We aimed to determine this association by addressing implications of selection, confounding and reverse causation. We conducted a nationwide, registry-based matched cohort study including all individuals diagnosed with MASLD in Denmark between 2000 and 2020, each with 5 age- and sex-matched references without liver disease. Dementia diagnoses were ascertained through hospital-, prescription-, and death registries. We estimated hazard ratios (HR) using cause-specific Cox regression, adjusting sequentially for comorbidities and socioeconomic status. Sensitivity analyses included age restrictions, delayed entry to address reverse causations, and a negative control outcome (Chronic Obstructive Pulmonary Disease (COPD)) to assess residual confounding from misclassification of alcohol consumption. We included 8,398 individuals with MASLD of which 174 developed dementia during follow-up and 41,990 references of which 641 developed dementia during follow-up. In unadjusted analyses, a MASLD diagnosis was associated with an increased risk of dementia (HR 1.40; 95% CI 1.17 \u2013 1.67). However, the association attenuated after adjustment for comorbidities and socioeconomic factors (HR 1.12; 95% CI 0.94\u20131.34). Delayed entry analyses suggested possible reverse causation as HRs tended to increase, suggesting underestimation. Using COPD as a negative control outcome showed no increased risk in MASLD patients. Although MASLD was not independently associated with increased dementia risk, our findings suggest possible reverse causation, theoretically reflecting that cognitive decline may cause weight loss, leading to underestimating the association.<\/jats:p>","DOI":"10.1007\/s11011-026-01796-x","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:51:23Z","timestamp":1770022283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term dementia risk in metabolic dysfunction-associated steatotic liver disease: a population-based study"],"prefix":"10.1007","volume":"41","author":[{"given":"Andreas","family":"Bartholdy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine Fr\u00f8sig","family":"Moseholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille Yde","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai J. Wewer","family":"Albrechtsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Lotte","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majken Karoline","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"7 Suppl","key":"1796_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/1403494810394718","volume":"39","author":"JS Andersen","year":"2011","unstructured":"Andersen JS, Olivarius NDF, Krasnik A (2011) The Danish National Health Service register. Scand J Public Health 39(7 Suppl):34\u20137","journal-title":"Scand J Public Health"},{"issue":"7 Suppl","key":"1796_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/1403494811405098","volume":"39","author":"M Baadsgaard","year":"2011","unstructured":"Baadsgaard M, Quitzau J (2011) Danish registers on personal income and transfer payments. Scand J Public Health 39(7 Suppl):103\u20135","journal-title":"Scand J Public Health"},{"issue":"2","key":"1796_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16224","volume":"45","author":"L Castera","year":"2025","unstructured":"Castera L, Alazawi W, Bugianesi E, Caussy C, Federici M, Romero-G\u00f3mez M et al (2025) A european survey to identify challenges in the management of metabolic dysfunction\u2010associated steatotic liver disease. Liver Int 45(2):e16224","journal-title":"Liver Int"},{"issue":"1","key":"1796_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01666-7","volume":"17","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK et al (2025) Evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease. Alzheimers Res Ther 17(1):14","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"1796_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282633","volume":"18","author":"M Cushman","year":"2023","unstructured":"Cushman M, Callas PW, Alexander KS, Wadley V, Zakai NA, Lidofsky SD et al (2023) Nonalcoholic fatty liver disease and cognitive impairment: a prospective cohort study. PLoS One 18(4):e0282633","journal-title":"PLoS One"},{"issue":"6","key":"1796_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R et al (2024) A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 390(6):497\u2013509","journal-title":"N Engl J Med"},{"issue":"1","key":"1796_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","volume":"23","author":"SA Harrison","year":"2025","unstructured":"Harrison SA, Frias JP, Lucas KJ, Reiss G, Neff G, Bollepalli S et al (2025) Safety and efficacy of efruxifermin in combination with a GLP-1 receptor agonist in patients with NASH\/MASH and type 2 diabetes in a randomized phase 2 study. Clin Gastroenterol Hepatol 23(1):103\u201313","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1796_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jpsychires.2023.03.041","volume":"161","author":"H Huang","year":"2023","unstructured":"Huang H, Liu Z, Xie J, Xu C (2023) Nafld does not increase the risk of incident dementia: a prospective study and meta-analysis. J Psychiatr Res 161:435\u2013440","journal-title":"J Psychiatr Res"},{"key":"1796_CR9","unstructured":"International Standard Classification of Education (ISCED) (2011) Paris: UNESCO; 2012"},{"issue":"7 Suppl","key":"1796_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/1403494810394715","volume":"39","author":"VM Jensen","year":"2011","unstructured":"Jensen VM, Rasmussen AW (2011) Danish education registers. Scand J Public Health 39(7 Suppl):91\u20134","journal-title":"Scand J Public Health"},{"issue":"3","key":"1796_CR11","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3350\/cmh.2021.0332","volume":"28","author":"S Jeong","year":"2022","unstructured":"Jeong S, Oh YH, Choi S, Chang J, Kim SM, Son JS et al (2022) Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults. Clin Mol Hepatol 28(3):510\u2013521","journal-title":"Clin Mol Hepatol"},{"issue":"12","key":"1796_CR12","doi-asserted-by":"publisher","DOI":"10.31083\/j.jin2312215","volume":"23","author":"Y Jin","year":"2024","unstructured":"Jin Y, Tang R, Wu L, Xu K, Chen X, Zhu Y et al (2024) Cognitive impairment in MASLD is associated with amygdala-related connectivity dysfunction in the prefrontal and sensory cortex. J Integr Neurosci 23(12):215","journal-title":"J Integr Neurosci"},{"key":"1796_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154455","volume":"115","author":"DA Koutoukidis","year":"2021","unstructured":"Koutoukidis DA, Koshiaris C, Henry JA, Noreik M, Morris E, Manoharan I et al (2021) The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 115:154455","journal-title":"Metabolism"},{"issue":"9","key":"1796_CR14","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1007\/s10620-020-06644-1","volume":"66","author":"C Labenz","year":"2021","unstructured":"Labenz C, Kostev K, Kaps L, Galle PR, Schattenberg JM (2021) Incident dementia in elderly patients with nonalcoholic fatty liver disease in Germany. Dig Dis Sci 66(9):3179\u20133185","journal-title":"Dig Dis Sci"},{"issue":"6","key":"1796_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.clinthera.2021.05.006","volume":"43","author":"R Litke","year":"2021","unstructured":"Litke R, Garcharna LC, Jiwani S, Neugroschl J (2021) Modifiable risk factors in Alzheimer disease and related dementias: a review. Clin Ther 43(6):953\u2013965","journal-title":"Clin Ther"},{"issue":"1","key":"1796_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-022-00930-w","volume":"14","author":"Y Lin","year":"2022","unstructured":"Lin Y, Feng X, Cao X, Miao R, Sun Y, Li R et al (2022) Age patterns of nonalcoholic fatty liver disease incidence: heterogeneous associations with metabolic changes. Diabetol Metab Syndr 14(1):181","journal-title":"Diabetol Metab Syndr"},{"issue":"12","key":"1796_CR17","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1080\/00365521.2022.2094725","volume":"57","author":"KP Lindvig","year":"2022","unstructured":"Lindvig KP, Wernberg CW, Kjaergaard M, Thorhauge KH, Alnor AB, Thiele M et al (2022) Only one-third of referrals for fatty liver disease are on time: real-world study reveals opportunities to avoid unnecessary and delayed referrals. Scand J Gastroenterol 57(12):1478\u20131485","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"1796_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","volume":"21","author":"M Lipsitch","year":"2010","unstructured":"Lipsitch M, Tchetgen ET, Cohen T (2010) Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology 21(3):383\u2013388","journal-title":"Epidemiology"},{"issue":"7 Suppl","key":"1796_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/1403494811401482","volume":"39","author":"E Lynge","year":"2011","unstructured":"Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public Health 39(7 Suppl):30\u20133","journal-title":"Scand J Public Health"},{"key":"1796_CR20","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.943417","volume":"30","author":"D Medina-Julio","year":"2024","unstructured":"Medina-Julio D, Ram\u00edrez-Mej\u00eda MM, Cordova-Gallardo J, Peniche-Luna E, Cant\u00fa-Brito C, Mendez-Sanchez N (2024) From liver to brain: how MAFLD\/MASLD impacts cognitive function. Med Sci Monit 30:e943417-1-e943417-13","journal-title":"Med Sci Monit"},{"issue":"8","key":"1796_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","volume":"35","author":"L Miao","year":"2024","unstructured":"Miao L, Targher G, Byrne CD, Cao YY, Zheng MH (2024) Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab 35(8):697\u2013707","journal-title":"Trends Endocrinol Metab"},{"issue":"7 Suppl","key":"1796_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1177\/1403494810395825","volume":"39","author":"O Mors","year":"2011","unstructured":"Mors O, Perto GP, Mortensen PB (2011) The Danish Psychiatric Central Research Register. Scand J Public Health 39(7 Suppl):54\u20137","journal-title":"Scand J Public Health"},{"issue":"11\u201312","key":"1796_CR23","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1111\/apt.18331","volume":"60","author":"PN Newsome","year":"2024","unstructured":"Newsome PN, Sanyal AJ, Engebretsen KA, Kliers I, \u00d8stergaard L, Vanni D et al (2024) Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial. Aliment Pharmacol Ther 60(11\u201312):1525\u201333","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"1796_CR24","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"E Nichols","year":"2022","unstructured":"Nichols E, Steinmetz JD, Vollset SE, Fukutaki K, Chalek J, Abd-Allah F et al (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health 7(2):e105\u2013e125","journal-title":"Lancet Public Health"},{"issue":"1","key":"1796_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12268","volume":"8","author":"CH N\u00f8rgaard","year":"2022","unstructured":"N\u00f8rgaard CH, Friedrich S, Hansen CT, Gerds T, Ballard C, M\u00f8ller DV et al (2022) Treatment with glucagon-like peptide\u20101 receptor agonists and incidence of dementia: data from pooled double\u2010blind randomized controlled trials and nationwide disease and prescription registers. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions 8(1):e12268","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"1","key":"1796_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000543","volume":"6","author":"NS Parikh","year":"2024","unstructured":"Parikh NS, Wahbeh F, Tapia C, Ianelli M, Liao V, Jaywant A et al (2024) Cognitive impairment and liver fibrosis in non-alcoholic fatty liver disease. BMJ Neurol Open 6(1):e000543","journal-title":"BMJ Neurol Open"},{"issue":"7 Suppl","key":"1796_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1403494810387965","volume":"39","author":"CB Pedersen","year":"2011","unstructured":"Pedersen CB (2011) The Danish Civil Registration System. Scand J Public Health 39(7 Suppl):22\u20135","journal-title":"Scand J Public Health"},{"issue":"3","key":"1796_CR28","first-page":"798","volume":"46","author":"A Potteg\u00e5rd","year":"2017","unstructured":"Potteg\u00e5rd A, Schmidt SAJ, Wallach-Kildemoes H, S\u00f8rensen HT, Hallas J, Schmidt M (2017) Data resource profile: the Danish National prescription registry. Int J Epidemiol 46(3):798\u2013798f","journal-title":"Int J Epidemiol"},{"issue":"3","key":"1796_CR29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000107084","volume":"24","author":"TKT Phung","year":"2007","unstructured":"Phung TKT, Andersen BB, H\u00f8gh P, Kessing LV, Mortensen PB, Waldemar G (2007) Validity of dementia diagnoses in the Danish hospital registers. Dement Geriatr Cogn Disord 24(3):220\u2013228","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"10","key":"1796_CR30","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1212\/01.wnl.0000271395.29695.9a","volume":"69","author":"C Reitz","year":"2007","unstructured":"Reitz C, den Heijer T, van Duijn C, Hofman A, Breteler MMB (2007) Relation between smoking and risk of dementia and Alzheimer disease. Neurology 69(10):998\u20131005","journal-title":"Neurology"},{"issue":"5\u20136","key":"1796_CR31","first-page":"292","volume":"34","author":"LC Salem","year":"2013","unstructured":"Salem LC, Andersen BB, Nielsen TR, Stokholm J, J\u00f8rgensen MB, Rasmussen MH et al (2013) Overdiagnosis of dementia in young Patients \u2013 A nationwide Register-Based study. Dement Geriatr Cogn Disord 34(5\u20136):292\u2013299","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"4","key":"1796_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E et al (2024) A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med 391(4):311\u2013319","journal-title":"N Engl J Med"},{"issue":"21","key":"1796_CR33","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS et al (2025) Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis. N Engl J Med 392(21):2089\u201399","journal-title":"N Engl J Med"},{"issue":"6","key":"1796_CR34","doi-asserted-by":"publisher","first-page":"e574","DOI":"10.1212\/WNL.0000000000200853","volume":"99","author":"Y Shang","year":"2022","unstructured":"Shang Y, Widman L, Hagstr\u00f6m H (2022) Nonalcoholic fatty liver disease and risk of dementia. Neurology 99(6):e574\u2013e582","journal-title":"Neurology"},{"issue":"1","key":"1796_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-05071-6","volume":"23","author":"K Shu","year":"2023","unstructured":"Shu K, Ye X, Song J, Huang X, Cui S, Zhou Y et al (2023) Disruption of brain regional homogeneity and functional connectivity in male NAFLD: evidence from a pilot resting-state fMRI study. BMC Psychiatry 23(1):629","journal-title":"BMC Psychiatry"},{"issue":"2","key":"1796_CR36","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jalz.2017.06.2637","volume":"14","author":"A Singh-Manoux","year":"2018","unstructured":"Singh-Manoux A, Dugravot A, Shipley M, Brunner EJ, Elbaz A, Sabia S et al (2018) Obesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II study. Alzheimers Dement 14(2):178\u2013186","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1796_CR37","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H (2024) MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 73(4):691\u2013702","journal-title":"Gut"},{"issue":"1","key":"1796_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/antiox14010056","volume":"14","author":"F Termite","year":"2025","unstructured":"Termite F, Archilei S, D\u2019Ambrosio F, Petrucci L, Viceconti N, Iaccarino R et al (2025) Gut microbiota at the crossroad of hepatic oxidative stress and MASLD. Antioxidants 14(1):56","journal-title":"Antioxidants"},{"key":"1796_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00930","volume":"12","author":"P Van Dyken","year":"2018","unstructured":"Van Dyken P, Lacoste B (2018) Impact of metabolic syndrome on neuroinflammation and the blood-brain barrier. Front Neurosci 12:930","journal-title":"Front Neurosci"},{"issue":"12","key":"1796_CR40","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","volume":"20","author":"W Wang","year":"2024","unstructured":"Wang W, Wang Q, Qi X, Gurney M, Perry G, Volkow ND et al (2024) Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: target trial emulation using nationwide real\u2010world data in the US. Alzheimers Dement 20(12):8661\u201372","journal-title":"Alzheimers Dement"},{"key":"1796_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.985109","volume":"14","author":"L Wang","year":"2022","unstructured":"Wang L, Sang B, Zheng Z (2022) Risk of dementia or cognitive impairment in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Front Aging Neurosci 14:985109","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"1796_CR42","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/EJE-19-0259","volume":"181","author":"IK Wium-Andersen","year":"2019","unstructured":"Wium-Andersen IK, Osler M, J\u00f8rgensen MB, Rungby J, Wium-Andersen MK (2019) Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case\u2013control study. Eur J Endocrinol 181(5):499\u2013507","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1796_CR43","doi-asserted-by":"publisher","first-page":"e565","DOI":"10.1212\/WNL.0000000000200770","volume":"99","author":"T Xiao","year":"2022","unstructured":"Xiao T, van Kleef L, Ikram MK, De Knegt R, Ikram MA (2022) Association of nonalcoholic fatty liver disease and fibrosis with incident dementia and cognition. Neurology 99(6):e565-73","journal-title":"Neurology"},{"issue":"1","key":"1796_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10654-017-0225-3","volume":"32","author":"W Xu","year":"2017","unstructured":"Xu W, Wang H, Wan Y, Tan C, Li J, Tan L et al (2017) Alcohol consumption and dementia risk: a dose-response meta-analysis of prospective studies. Eur J Epidemiol 32(1):31\u201342","journal-title":"Eur J Epidemiol"},{"issue":"Suppl","key":"1796_CR45","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L (2025) Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol 31(Suppl):S32\u201350","journal-title":"Clin Mol Hepatol"},{"issue":"S3","key":"1796_CR46","doi-asserted-by":"publisher","first-page":"e047353","DOI":"10.1002\/alz.047353","volume":"16","author":"AL Zhou","year":"2020","unstructured":"Zhou AL, Swaminathan SK, Gali CC, Bruinsma TJ, Curran GL, Sarma VV et al (2020) Blood-brain barrier insulin resistance decreases insulin uptake and increases amyloid beta uptake in alzheimer\u2019s disease brain. Alzheimer\u2019s Dement 16(S3):e047353","journal-title":"Alzheimer\u2019s Dement"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-026-01796-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-026-01796-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-026-01796-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:05:04Z","timestamp":1770026704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-026-01796-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1796"],"URL":"https:\/\/doi.org\/10.1007\/s11011-026-01796-x","relation":{},"ISSN":["1573-7365"],"issn-type":[{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MKJ has received a consultant fee from Pfizer on an unrelated liver project. LLG has recieved grants from Novo Nordisk, Alexion, Pfizer, Beckton Dickinson, Bayer, and Sobi International, and personal fees from AstraZeneca, Novo Nordisk, and Boehringer Ingelheim not related to this work. NJWA. has received research support, personal fees, and speaker fees from EvoSep, Mercodia, Novo Nordisk, Merck\/MSD, Roche, and Boehringer Ingelheim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}